Innovative MedTech Rebrands as AnTix Holdings, Shifts Focus to AI-Powered Ticketing Technology

Innovative MedTech, Inc. has completed its corporate rebranding and name change to AnTix Holdings, Inc., marking a fundamental shift in the company's strategic direction from medical technology to the online ticketing and entertainment technology sector. The company, which previously operated under the ticker symbol IMTH on the OTC market, filed a Certificate of Amendment with the State of Delaware on September 19, 2025, to formalize the name change from Innovative MedTech, Inc. to AnTix Holdings, Inc.

Michael J. Friedman, President and CEO of the newly named AnTix Holdings, stated that the rebranding reflects the company's expansion into the growing online ticketing market, where it plans to apply artificial intelligence and Web 3.0 tools to improve the ticketing and live experience for consumers and partners. According to Friedman, the company's ticketing technology has already begun generating revenues, providing what he described as a strong foundation for the next phase of growth. The company's goal is to build value through innovation, execution, and acquisition in what Friedman characterized as a market ripe for significant technological change.

The strategic importance of this announcement lies in the complete transformation of the company's business model from medical technology to entertainment technology. While the company will continue trading under the IMTH ticker symbol temporarily, it intends to file with FINRA to change to a new ticker symbol that better reflects its new focus. This shift represents a dramatic pivot for a company that previously specialized in medical technology, now positioning itself to compete in the highly competitive online ticketing industry dominated by established players.

For investors and industry observers, this announcement signals a company attempting to capitalize on what management perceives as meaningful opportunities in the ticketing technology space. The move into artificial intelligence-powered ticketing solutions could potentially disrupt traditional ticketing models by introducing greater transparency, efficiency, and personalization to the industry. The company's website at https://www.antixholdings.com provides additional information about its new direction and technology offerings.

Despite the complete business model shift, the company maintains its connection to its medical technology roots through its exclusive licensing agreement for the Oral Thrush application of Shear Kershman Labs' BioViscid™ bio-adhesive encapsulation. This dual focus suggests the company may be maintaining some medical technology assets while primarily pursuing growth in the ticketing sector. The transformation raises questions about how effectively a medical technology company can pivot to compete in the crowded and technologically sophisticated ticketing industry, where established platforms already dominate market share.

The company's forward-looking statements emphasize that these plans are subject to numerous risks and uncertainties, including general economic conditions, market competition, availability of capital, and the ability to successfully execute the new business strategy. The success of this strategic pivot will depend on the company's ability to differentiate its AI-powered ticketing solutions in a market where technological innovation is increasingly becoming a key competitive factor.